{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient+Safety",
    "query": {
      "condition": "Patient Safety"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11207,
    "total_pages": 1121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Patient+Safety&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T04:10:57.651Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02092948",
      "title": "Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer",
        "Pancreatic Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "[124I] PSCA-Minibody PET/CT imaging of the whole body",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2013-08-22",
      "completion_date": "2017-01-06",
      "has_results": false,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02092948"
    },
    {
      "nct_id": "NCT00738738",
      "title": "6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Generalized Anxiety Disorder"
      ],
      "interventions": [
        {
          "name": "PD-0332334",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-01",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2012-12-03",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Prairie Village, Kansas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Prairie Village",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00738738"
    },
    {
      "nct_id": "NCT00927238",
      "title": "XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Degenerative Disc Disease"
      ],
      "interventions": [
        {
          "name": "XL TDR",
          "type": "DEVICE"
        },
        {
          "name": "Lumbar fusion surgery",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "NuVasive",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 246,
      "start_date": "2009-07",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-07-30",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 17,
      "location_summary": "Campbell, California • Thousand Oaks, California • Durango, Colorado + 14 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Durango",
          "state": "Colorado"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00927238"
    },
    {
      "nct_id": "NCT01290549",
      "title": "A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Hodgkins Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2011-03-22",
      "completion_date": "2014-11-18",
      "has_results": false,
      "last_update_posted_date": "2017-06-16",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Sarasota, Florida • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Germantown",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01290549"
    },
    {
      "nct_id": "NCT04401748",
      "title": "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 531,
      "start_date": "2020-09-10",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 58,
      "location_summary": "Fullerton, California • Los Angeles, California • Torrance, California + 50 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401748"
    },
    {
      "nct_id": "NCT00166543",
      "title": "Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TAS-108",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SRI International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 146,
      "start_date": "2004-05",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2015-08-18",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00166543"
    },
    {
      "nct_id": "NCT03782415",
      "title": "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "GBM",
        "Newly Diagnosed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "MN-166",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-12-29",
      "completion_date": "2023-08-07",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782415"
    },
    {
      "nct_id": "NCT06698315",
      "title": "Evidence-based Approach to Reduce Falls in Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Falls with Injuries"
      ],
      "interventions": [
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Methodist Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2024-07-23",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698315"
    },
    {
      "nct_id": "NCT00675935",
      "title": "Falls - Tailoring Interventions for Patient Safety",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patient Falls"
      ],
      "interventions": [
        {
          "name": "Fall Prevention Tool Kit prototype using a randomized design",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 10264,
      "start_date": "2007-09",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-17",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675935"
    },
    {
      "nct_id": "NCT02648490",
      "title": "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumour"
      ],
      "interventions": [
        {
          "name": "HLX07",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "5-HT3 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henlix, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2016-09",
      "completion_date": "2019-06-28",
      "has_results": false,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-06-11T04:10:57.651Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02648490"
    }
  ]
}